29 June 2021
: Case report 
A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab
Unusual or unexpected effect of treatment, Adverse events of drug therapy
Sonya K. Kedzior12EF, Gabrielle Jacknin2E, Andi Hudler3E, Scott W. Mueller12E, Tyree Heath Kiser
12ACDEG*
DOI: 10.12659/AJCR.931702
Am J Case Rep 2021; 22:e931702
Table 1. Laboratory results on admission.
| Laboratory parameter | Value | Reference |
|---|---|---|
| Serum sodium | 123 | 133–145 mmol/L |
| Serum potassium | 7.1 | 3.5–5.1 mmol/L |
| Serum chloride | 85 | 98–108 mmol/L |
| Serum glucose | 1123 | 70–199 mg/dL |
| Anion gap | 34 | 4–16 mmol/L |
| Hemoglobin A1c | 8.3 | ≤5.6% |
| Beta hydroxybutyrate | >8.00 | ≤0.27 mmol/L |
| Lactate | 4.7 | 0.5–2.2 mmol/L |
| Venous pH | 6.943 | 7.330–7.430 |
| Venous pCO2 | 30 | 36–48 mmHg |
| Venous bicarbonate | 6.1 | 22–26 mmol/L |
| Serum c-peptide | 0.1 | 0.8–5.2 ng/mL |
| Glutamic acid decarboxylase | >250 | 0.0–5.0 IU/mL |
| (GAD65) antibody | ||
| T4 free | 1.05 | 0.89–1.76 ng/dL |
| Thyroid stimulating hormone (TSH) | 0.23 | 0.45–5.33 mIU/L |